RA CAPITAL MANAGEMENT, L.P. - 11 Apr 2024 Form 4 Insider Report for Acrivon Therapeutics, Inc. (ACRV)

Role
Director, 10%+ Owner
Signature
/s/ Peter Kolchinsky, Manager of RA Capital Management, L.P.
Issuer symbol
ACRV
Transactions as of
11 Apr 2024
Net transactions value
+$30,005,000
Form type
4
Filing time
15 Apr 2024, 16:15:12 UTC
Previous filing
04 Apr 2024
Next filing
30 Apr 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ACRV Common Stock Award $30,005,000 +3,530,000 +81% $8.50 7,914,206 11 Apr 2024 See footnotes F1, F2
holding ACRV Common Stock 426,302 11 Apr 2024 See footnotes F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Held directly by RA Capital Healthcare Fund, L.P. (the "Fund").
F2 RA Capital Management, L.P. (the "Adviser") is the investment manager for the Fund and RA Capital Nexus Fund II, L.P. (the "Nexus Fund II"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, Dr. Kolchinsky, and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein.
F3 Held directly by Nexus Fund II.

Remarks:

Dr. Derek DiRocco, a Partner of the Adviser, serves on the Issuer's board of directors.